Article Text

PDF
Original research
Mechanical thrombectomy of M1 and M2 middle cerebral artery occlusions
  1. Hisham Salahuddin1,
  2. Guru Ramaiah1,
  3. Diana E Slawski1,
  4. Julie Shawver2,
  5. Mark Buehler3,
  6. Syed F Zaidi1,
  7. Mouhammad Jumaa1
  1. 1Department of Neurology, University of Toledo Medical Center, Toledo, Ohio, USA
  2. 2Department of Neurology, Promedica Toledo Hospital, Toledo, Ohio, USA
  3. 3Department of Radiology, University of Toledo Medical Center, Toledo, Ohio, USA
  1. Correspondence to Mouhammad Jumaa, Department of Neurology, University of Toledo Medical Center, 3000 Arlington Ave, MS 1195, Toledo, Ohio 43537, USA; mouhammad.jumaa{at}utoledo.edu

Abstract

Background Over half of patients who receive intravenous tissue plasminogen activator for middle cerebral artery division (MCA-M2) occlusion do not recanalize, leaving a large percentage of patients who may need mechanical thrombectomy (MT). However, the outcomes of MT for M2 occlusion have not been well characterized.

Objective To determine if MT of M2 occlusion is as safe and efficacious as current standard-of-care MT for M1 occlusions.

Methods With institutional review board approval, we retrospectively reviewed records of 212 patients undergoing MT for isolated MCA M1 or M2 occlusions during a 36-month period (Sept 2013 to Sept 2016) at two centres. Treatment variables, clinical outcomes, and complications in each group were recorded.

Results There were 153 M1 MCA occlusions and 59 M2 MCA occlusions. No statistically significant difference was found in the rate of mortality (20% in M1 vs 13.6% in M2, p=0.32), excellent (34.5% vs 37.3%, p=0.75) or good (51% vs 55.9%, p=0.54) clinical outcomes between the two groups. Infarct volumes (48.4 mL vs 46.2 mL, p=0.62) were comparable between the two groups, as were the rates of hemorrhagic (3.3% vs 3.4%, p=1.0) and procedural complications (3.3% vs 5.1%, p=0.69).

Conclusion Our data on MT targeting M2 occlusions demonstrates reasonable safety and functional outcomes. Further randomized clinical trials are needed to clarify which patients may benefit from MT for M2 occlusions.

  • intervention
  • stroke
  • thrombectomy
  • device thrombolysis

Statistics from Altmetric.com

Footnotes

  • Contributors HS made substantial contributions to the conception and design of the work, the acquisition, analysis, and interpretation of data, and drafted the research. GR, DES, JS made substantial contributions to the acquisition, analysis, and interpretation of data. MB made substantial contributions to the acquisition, analysis, and interpretation of data, and revised it critically for important intellectual content. SFZ made substantial contributions by revising the research critically for important intellectual content. MJ made substantial contributions to the conception and design of the work and revised it critically for important intellectual content.

  • Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Ethics approval Hospital institutional review board.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement Unpublished data are available upon request from the corresponding author.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.